Serum miR-21 predicts the prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma

  • Qing Ji Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Ting Jiang Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
  • Jun Su Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Suyuan Zhang Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Chengfang Li Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Xiaorong Yang Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Xinglong Wu Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Jin Yao Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Dan Yuan Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Jinjing Wang Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China
DOI: https://doi.org/10.18388/abp.2020_5816

Abstract

Background: Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) lacks specific clinical manifestations and its malignancy renders prognostication and choice of treatment strategy difficult. The aim of this study was to evaluate microRNA (miR)-21 as potential non-invasive biomarkers for prognosis in PGI-DLBCL patients. Methods: Serum miR-21 expression in de novo PGI-DLBCL patients, consecutively enrolled for this study, was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Relative expression was calculated using the comparative Ct method. Statistical significance was determined using the Mann-Whitney rank sum and Fisher’s exact test. Survival analysis was conducted using the Kaplan-Meier method. Results: Compared with healthy controls, serum miR-21 levels were significantly elevated in the PGI-DLBCL patients (n=156). The high expression level of serum miR-21 at diagnosis was associated with worse progression-free survival (PFS) (30 (9–42) vs 42 (12–52) months in high and low miR-21 groups) and overall survival (OS) (35 (15–52) vs 48 (17–61) months in high and low miR-21 groups) and was an independent risk factor for PFS and OS (hazard ratios 4.345 and 3.311, respectively). Furthermore, Bcl-2, Bcl-6 and Ki-67 were independently and positively associated with miR-21 expression. Conclusions: Our results suggest that miR-21 is a potential prognostic marker to predict clinical outcomes in PGI-DLBCL patients and a high miR-21 level is associated with poor outcomes.

Published
2022-06-12
Issue
Vol. 69 No. 2 (2022)
Section
Articles

Copyright (c) 2022 Qing Ji, Ting Jiang, Jun Su, Suyuan Zhang, Chengfang Li, Xiaorong Yang, Xinglong Wu, Jin Yao, Dan Yuan, Jinjing Wang

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Acta Biochimica Polonica is an open access quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made, ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. There are no additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright for all published papers © stays with the authors.

Copyright for the journal: © Polish Biochemical Society.